Free tool
FAERS Monitor: Oxytrol For Women
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202211 or its brand name (Oxytrol For Women, Oxybutynin). Reports on generic versions are filed under their own applications.
Reports
28,263
Serious
13,571
48% of reports
Hospitalization
6,767
Death reported
1,688
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,815
- fatigue1,549
- fall1,463
- off label use1,258
- nausea1,218
- dizziness1,122
- diarrhoea1,110
- pain1,071
- urinary tract infection1,045
- headache986
- pruritus950
- asthenia900
- application site erythema826
- rash792
- dyspnoea745
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 178 |
| 2005 | 196 |
| 2006 | 150 |
| 2007 | 43 |
| 2008 | 55 |
| 2009 | 90 |
| 2010 | 345 |
| 2011 | 572 |
| 2012 | 725 |
| 2013 | 1,492 |
| 2014 | 5,252 |
| 2015 | 2,300 |
| 2016 | 1,799 |
| 2017 | 1,880 |
| 2018 | 2,030 |
| 2019 | 2,054 |
| 2020 | 1,776 |
| 2021 | 1,500 |
| 2022 | 1,477 |
| 2023 | 1,350 |
| 2024 | 1,023 |
| 2025 | 1,144 |
| 2026 | 831 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,025,896 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site erythemaSignal | 826 | 24.2 | 22.6 | 17,779 |
| urinary tract infectionSignal | 1,045 | 4.6 | 4.3 | 2,928 |
| fallSignal | 1,463 | 3.3 | 3.1 | 2,345 |
| drug ineffectiveSignal | 3,815 | 2.2 | 2.1 | 2,519 |
| pruritus | 950 | 1.8 | 1.7 | 370 |
| asthenia | 900 | 1.8 | 1.7 | 314 |
| dizziness | 1,122 | 1.7 | 1.6 | 312 |
| fatigue | 1,549 | 1.5 | 1.4 | 251 |
| rash | 792 | 1.4 | 1.3 | 74 |
| pain | 1,071 | 1.3 | 1.2 | 75 |
| diarrhoea | 1,110 | 1.3 | 1.2 | 70 |
| headache | 986 | 1.2 | 1.1 | 25 |
| nausea | 1,218 | 1.1 | 1.1 | 23 |
| off label use | 1,258 | 1.1 | 1.0 | 6 |
| dyspnoea | 745 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.